



# Indicator Analysis 2025

## of the Certified Prostate Cancer Centres

Audit year 2024 / Indicator year 2023

## Table of Content

Introduction .....	3
General Information .....	3
Status of the certification system: Prostate Cancer Centres 2024 .....	5
Clinical sites taken into account .....	6
Tumour documentation systems in the centre's clinical sites .....	7
Basic data .....	8
Analysis of indicators .....	15
Indicator No. 1a: Number of primary cases of prostate cancer .....	15
Indicator No. 1b1: Distribution of primary cases with locally confined prostate carcinoma (PCa) and low risk .....	16
Indicator No. 1b2: Distribution of primary cases with locally confined prostate cancer and intermediate risk .....	17
Indicator No. 1b3: Distribution of primary cases with locally confined prostate cancer and high risk .....	18
Indicator No. 1c: Patients with new recurrence and/or distant metastasis .....	19
Indicator No. 2a: Presentation at the weekly pre-therapeutic tumour board – Urology .....	20
Indicator No. 2b: Presentation at the weekly pre-therapeutic tumour board – Radiotherapy .....	21
Indicator No. 3a: Presentation in the weekly tumour board - Primary cases post-operative .....	22
Indicator No. 3b: Presentation in the weekly tumour board - Primary cases with primary M1 pre-therapeutic .....	23
Indicator No. 3c: Presentation in the weekly tumour board - Recurrence/metastasis pre-therapeutic .....	24
Indicator No. 4: Active-Surveillance (AS) (GL QI) .....	25
Indicator No. 5: Percutaneous RT with hormone ablation therapy for locally confined PCa with high risk (GL QI) .....	26
Indicator No. 6: Psycho-oncological distress screening .....	27
Indicator No. 7: Social service counselling .....	28
Indicator No. 8: Patients enrolled in a study .....	29
Indicator No. 9: Surgical expertise .....	32
Indicator No. 10: Record of R1 resections for (y)pT2 c / pN0 or Nx M0 .....	33
Indicator No. 11: Definitive radiotherapy .....	34
Indicator No. 12: Permanent seed implantation - D 90 > 130 Gy .....	35
Indicator No. 13: HDR brachytherapy .....	36
Indicator No. 14: Diagnostic report - Punch biopsy (GL QI) .....	37
Indicator No. 15: Diagnostic report - Lymph nodes (GL QI) .....	38
Indicator No. 16: Begin Salvage-radiotherapy for recurrent prostate cancer (GL QI) .....	39
Indicator No. 17: Postoperative complications after radical prostatectomy (RP) (GL QI) .....	40
Indicator No. 18: Adverse effects after radiotherapy (GL QI) .....	41
Indicator No. 19: Dental examination prior to bisphosphonate or denosumab therapy (GL QI) .....	42
Indicator No. 20: No hormone ablation therapy in the case of locally advanced prostate carcinoma with radical prostatectomy (GL QI) .....	43
Indicator No. 21: Focal therapy for locally advanced prostate cancer (GL QI) .....	44
Indicator No. 22: Rate of locally confined prostate carcinoma and low risk with RPE/RCE .....	45
Indicator No. 23: RPE/RCE in primary cases with locally confined prostate carcinoma and low risk .....	46
Imprint .....	47

General information

Indicator No. 11:	Definitive radiotherapy .....
Indicator No. 12:	Permanent seed implantation - D 90 > 130 Gy .....
Indicator No. 13:	HDR brachytherapy .....
Indicator No. 14:	Diagnostic report - Punch biopsy (GL QI) .....
Indicator No. 15:	Diagnostic report - Lymph nodes (GL QI) .....

Quality indicators of the guidelines (LL QI):

In the table of contents and in the respective headings, the indicators which correspond to the quality indicators of the evidence-based guidelines are specifically identified. These quality indicators are based on the strong recommendations of the guidelines and were derived from the guidelines groups in the context of the German Guideline Programme in Oncology (GGPO). Further information: [www.leitlinienprogramm-onkologie.de](http://www.leitlinienprogramm-onkologie.de)\*

The quality indicators (QIs) refer to version 6.2 of the S3 GL on early detection, diagnosis and therapy of the different stages of prostate cancer.

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients total
Numerator	Patients of the denominator presented at the tumour board (post-operative: primary cases operated)	44*	7 - 1143	11007
Denominator	Primary cases > pT3a and/or R1 and/or pN+	46*	7 - 1168	11979
Rate	Target value = 100%	100%	39.07% - 100%	91.89%**

Basic data indicator:

The definition of the **numerator**, **denominator** and the **target value** are taken from the data sheet.

The **median** for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

**Range** specifies the value range for the numerator, denominator and ratio of all centres.

The column **Patients Total** displays the total of all patients treated according to the indicator and the corresponding quota.





Diagram:

The x-axis indicates the number of centres and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.


\*For further information on the methodological approach see „Development of guideline-based quality indicators“ ([https://www.leitlinienprogramm-onkologie.de/fileadmin/user\\_upload/Downloads/Methodik/QIEP\\_OL\\_2021\\_Version\\_3\\_english\\_version.pdf](https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2021_Version_3_english_version.pdf))

General information



Cohort development:

The cohort development in the years 2019, 2020, 2021, 2022 and 2023 is presented in a box plot diagram. This chart provides the distribution overview of each cohort’s indicator year and direct comparison to the previous year.



Boxplot:

A box plot consists of a **box with median, whiskers** and **outliers**. 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box cover 90% of the centres. The extreme values are depicted here as dots.

Status of the certification system: Prostate Cancer Centres 2024

	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020	31.12.2019
Ongoing certification procedures	11	7	5	11	22	6
Certified centres	172	161	156	146	131	127
Certified clinical sites	174	163	157	147	132	128

## Clinical sites taken into account

	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020	31.12.2019
Sites included in the Annual Report	165	153	145	132	124	122
Correspond to	94.8%	93.8%	92.3%	89.8%	93.9%	95.3%
Primary cases total*	44,882	39,943	36,135	30,336	30,528	29,344
Primary cases per site (mean)*	272	261	249	230	246	241
Primary cases per site (median)*	211	196	180	172	171	170


\*The figures are based on the clinical sites listed in the Annual Report.

This Annual Report looks at the Prostate Cancer Centres certified in the Certification System of the German Cancer Society. The basis for the diagrams in the Annual Report is the Data Sheet.

The Annual Report includes 165 of the 174 certified centre sites. Excluded are 5 sites that were certified for the first time in 2024 and 1 clinical site that was reinstated (data mapping of complete calendar year not mandatory for initial certifications). Another 3 clinical sites were unable to submit a final Data Sheet by the data cutoff date of 31.01.2025. A total of 46,234 primary cases of prostate cancer were treated at 174 clinical sites. A current overview of all certified sites is shown at [www.oncomap.de](http://www.oncomap.de).

The indicators published here refer to the indicator year 2023. They are the basis for the audits conducted in 2024.

Tumour documentation systems used in Prostate Cancer Centres




Andere = other  
KIS-Erweiterung = KIS enlargement  
Tumorzentrum = tumour centre

Legende:	
Andere („others“)	System used in ≤ 3 clinical sites

The details on the tumour documentation system was taken from the Data Sheet (Basic Data Sheet). It is not possible to use more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.

Basic data – Primary cases prostate cancer


Total primary cases



	Total primary cases
Locally confined (T1/2, N0, M0), Low risk	7,484 (16.67%)
Locally confined (T1/2, N0, M0), Intermediate risk	18,618 (41.48%)
Locally confined (T1/2, N0, M0), High risk	11,356 (25.30%)
Locally advanced (T3/4, N0, M0)	1,917 (4.27%)
Advanced (N1, M0)	1,066 (2.38%)
Advanced (N0/1, M1)	3,035 (6.76%)
Not classified <sup>1)</sup>	1,406 (3.13%)
Total primary cases	44,882

1) Not classified:- Nx, Mx, incidental findings after radical cystoprostatectomy




**Basic data – Distribution non-interventional / interventional primary cases Prostate Cancer**
**Non-interventional / interventional primary cases**


	Non interventional <sup>1)</sup>	Interventional	Total
Locally confined (T1/2, N0, M0), Low risk	3,080 (41.15%)	4,404 (58.85%)	7,484 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	1,053 (5.66%)	17,565 (94.34%)	18,618 (100%)
Locally confined (T1/2, N0, M0), High risk	260 (2.29%)	11,096 (97.71%)	11,356 (100%)
Locally advanced (T3/4, N0, M0)	52 (2.71%)	1,865 (97.29%)	1,917 (100%)
Advanced (N1, M0)	6 (0.56%)	1,060 (99.44%)	1,066 (100%)
Advanced (N0/1, M1)	26 (0.86%)	3,009 (99.14%)	3,035 (100%)
Not classified <sup>2)</sup>	182 (12.94%)	1,224 (87.06%)	1,406 (100%)
<b>Total primary cases</b>	<b>4,659</b>	<b>40,223</b>	<b>44,882</b>

1) Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory PCa

2) Not classified : Nx, Mx, incidental findings after radical cystoprostatectomy

Basic data - Distribution of therapies Prostate Cancer




	Non-interventional <sup>1)</sup>		Total
	Active-Surveillance <sup>1)</sup>	Watchful Waiting <sup>1)</sup>	
Locally confined (T1/2, N0, M0), Low risk	2,685 (87.18%)	395 (12.82%)	3,080 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	704 (66.86%)	349 (33.14%)	1,053 (100%)
Locally confined (T1/2, N0, M0), High risk	91 (35.00%)	169 (65.00%)	260 (100%)
Total primary cases (locally confined), non-interventional treatment	3,480	913	4,393

1) Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory

## Basic data - Distribution of therapies Prostate Cancer

### Primary cases - Distribution of therapies




	Non-interventional (Active surveillance, Watchful waiting)	Interventional - local treatment of the prostate <sup>1)</sup>	Interventional - exclusive systemic treatment	Interventional - other non- local treatment <sup>2)</sup>	Total
Locally confined (T1/2, N0, M0), Low risk	3,080 (41.15%)	4,352 (58.15%)	15 (0.20%)	37 (0.49%)	7,484 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	1,053 (5.66%)	17,297 (92.90%)	119 (0.64%)	149 (0.80%)	18,618 (100%)
Locally confined (T1/2, N0, M0), High risk	260 (2.29%)	10,497 (92.44%)	394 (3.47%)	205 (1.81%)	11,356 (100%)
Locally advanced (T3/4, N0, M0)	52 (2.71%)	1,733 (90.40%)	91 (4.75%)	41 (2.14%)	1,917 (100%)
Advanced (N1, M0)	6 (0.56%)	899 (84.33%)	115 (10.79%)	46 (4.32%)	1,066 (100%)
Advanced (N0/1, M1)	26 (0.86%)	554 (18.25%)	1,842 (60.69%)	613 (20.20%)	3,035 (100%)
Not classified <sup>2)</sup>	182 (12.94%)	1,151 (81.86%)	49 (3.49%)	24 (1.71%)	1,406 (100%)
<b>Total primary cases</b>	<b>4,659</b>	<b>36,483</b>	<b>2,625</b>	<b>1,115</b>	<b>44,882</b>

1) Interventional - local treatment of the prostate: e.g. radical prostatectomy (RP), radical cystoprostatectomy (CPE), definitive percutaneous radiation, brachytherapy,

2) Interventional - other non-local treatment: e.g. palliative radiation of bone metastases, best supportive care.


3) Not classified: Nx, Mx, incidental findings after radical cystoprostatectomy (CPE).

Basic data – Primary case distribution in the indicator years 2019-2023



## Basic data – Distribution of interventional local therapies Prostate Cancer

### Interventional primary cases treated - Distribution of therapies



	Interventional – local treatment of prostata							Total
	PE <sup>1)</sup>	CPE <sup>2)</sup> due to PCa	Incidental finding after CPE <sup>2)</sup>	Definitive percutaneous radiotherapy	LDR brachytherapy	HDR brachytherapy	Other local therapy <sup>3)</sup>	
Locally confined (T1/2, N0, M0) Low risk	3,433 (78.88%)	17 (0.9%)	0 (0.00%)	625 (14.36%)	201 (4.62%)	13 (0.30%)	63 (1.45%)	4,352 (100.00%)
Locally confined (T1/2, N0, M0) Intermediate risk	13,530 (78.22%)	20 (0.12%)	0 (0.00%)	3,447 (19.93%)	132 (0.76%)	67 (0.39%)	101 (0.58%)	17,297 (100.00%)
Locally confined (T1/2, N0, M0) High risk	7,905 (75.31%)	27 (0.26%)	0 (0.00%)	2,487 (23.69%)	15 (0.14%)	49 (0.47%)	14 (0.13%)	10,497 (100.00%)
Locally advanced (T3/4, N0, M0)	1,131 (65.26%)	14 (0.81%)	0 (0.00%)	583 (33.64%)	0 (0.00%)	3 (0.17%)	2 (0.12%)	1,733 (100.00%)
Advanced (N1, M0)	533 (59.29%)	4 (0.44%)	0 (0.00%)	358 (39.82%)	0 (0.00%)	4 (0.44%)	0 (0.00%)	899 (100.00%)
Advanced (N0/1, M1)	238 (42.96%)	0 (0.00%)	0 (0.00%)	313 (56.50%)	0 (0.00%)	1 (0.18%)	2 (0.36%)	554 (100.00%)
Not classified <sup>4)</sup>	63 (5.47%)	6 (0.52%)	1,018 (88.44%)	51 (4.43%)	8 (0.70%)	0 (0.00%)	5 (0.43%)	1,151 (100.00%)
<b>Total primary cases</b>	<b>26,833</b>	<b>88</b>	<b>1,018</b>	<b>7,864</b>	<b>356</b>	<b>137</b>	<b>187</b>	<b>36,383</b>

1) Radical Prostatectomy (PE)


3) Other therapies: i.e. HIFU, ...

2) Radical cystoprostatectomy (CPE)


4) Not classified : Nx, Mx, incidental finding after radical cystoprostatectomy (CPE)

## Basic data - Distribution of therapies of prostate cancer patients with recurrence and metastasis

### Newly diagnosed recurrence – distribution of therapies



### Newly diagnosed remote metastasis – distribution of therapies



	Active-Surveillance	Watchful Waiting	PE <sup>1</sup>	CPE <sup>2</sup> due to Pca	Incidental finding after CPE	Definitive percutaneous radiotherapy	LDR-Brachy-Therapy	HDR-Brachy-Therapy	other local Therapie <sup>3</sup>	Exclusive systemic therapy	Other therapy <sup>4</sup>	Total
Pat. with newly diagnosed recurrence	0 (0.00%)	91 (2.29%)	103 (2.59%)	16 (0.40%)	0 (0.00%)	1,957 (49.21%)	2 (0.05%)	32 (0.80%)	51 (1.28%)	492 (12.37%)	1,233 (31.00%)	3,977 (100%)
Pat. with newly diagnosed remote metastasis	0 (0.00%)	19 (0.85%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	707 (31.79%)	1,498 (67.36%)	2,224 (100%)


1) Radical Prostatectomy (PE)

2) Radical Cystoprostatectomy (CPE)


3) Other therapies: i.e. HIFU, ...

4) Not classified: Nx, Mx, incidental finding after radical cystoprostatectomy

1a. Number of primary cases of Prostate Cancer



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients total
Number	Primary cases	211	100 - 2667	44882
	Target value $\geq 100$			




	2019	2020	2021	2022	2023
Max	2768,00	2660,00	2711,00	2512,00	2667,00
95 <sup>th</sup> percentile	451,50	502,55	522,40	581,20	568,00
75 <sup>th</sup> percentile	274,00	244,25	277,00	278,00	301,00
Median	171,00	171,50	180,00	196,00	211,00
25 <sup>th</sup> percentile	143,75	131,75	141,00	150,00	163,00
5 <sup>th</sup> percentile	114,00	107,00	110,80	116,20	124,00
Min	101,00	86,00	89,00	102,00	100,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	165	100.00%

**Comments:**  
The positive trend in the number of primary cases continued across the entire spectrum in the current indicator year. The number of primary cases rose by 12.4% compared with the previous year, while the median number of primary cases treated in the centres rose by 7.7%. All centres met the target value of at least 100 primary cases. Based on the current incidence rate for 2022 (database, Robert-Koch-Institut 74895), the coverage of primary cases treated in German centres is 54.6% (previous year: 54.7%).

1b1. Distribution of primary cases with locally confined Prostate Cancer and low risk



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients total
Number	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and Gleason score 6 and cT category ≤ 2a)	36	4 - 377	7484
	No target value			




	2019	2020	2021	2022	2023
Max	423,00	425,00	403,00	445,00	377,00
95 <sup>th</sup> percentile	81,85	82,90	84,00	96,20	97,00
75 <sup>th</sup> percentile	44,50	44,00	49,00	54,00	52,00
Median	32,00	29,00	29,00	31,00	36,00
25 <sup>th</sup> percentile	20,00	18,00	19,00	22,00	25,00
5 <sup>th</sup> percentile	11,00	10,00	9,20	12,60	12,20
Min	5,00	5,00	2,00	5,00	4,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	-----	-----
<b>Comments:</b> In 37,458 patients (= 83.5% of all primary cases), the carcinoma was diagnosed at a locally confined stage (T1/2 N0 M0); of these, 7,484 – and thus one fifth of the locally confined tumours – were classified as low risk.			



1b2. Distribution of primary cases with locally confined Prostate Cancer and intermediate risk



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Number	Primary cases with locally confined Pca and intermediate risk (PSA > 10-20 ng/ml or Gleason score 7 or cT 2b)	78	20 - 1546	18618
	No target value			




	2019	2020	2021	2022	2023
Max	1615,00	1557,00	1571,00	1373,00	1546,00
95 <sup>th</sup> percentile	189,00	194,65	218,00	246,20	258,40
75 <sup>th</sup> percentile	96,25	94,25	107,00	112,00	125,00
Median	64,50	60,00	67,00	70,00	78,00
25 <sup>th</sup> percentile	47,75	45,50	47,00	54,00	61,00
5 <sup>th</sup> percentile	26,15	25,65	29,00	32,00	38,20
Min	10,00	9,00	15,00	15,00	20,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	----	----

**Comments:**  
The proportion of primary cases with locally confined carcinoma (T1/2) and medium risk has increased almost continuously since 2014 from 35% and now stands at 41.5% of all primary cases for the first time. This increase is also reflected in the development of treatment figures across the entire spectrum. On average, 78 primary cases of locally confined prostate cancer with medium risk were treated in the centres.

1b3. Distribution of primary cases with locally confined Prostate Cancer and high risk



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Number	Primary cases with locally confined Pca and high risk (PSA > 20 ng/ml or Gleason score ≥ 8 or cT2c)	55	20 - 570	11356
	No target value			




	2019	2020	2021	2022	2023
Max	660,00	627,00	654,00	515,00	570,00
95 <sup>th</sup> percentile	147,20	155,70	152,80	155,60	161,60
75 <sup>th</sup> percentile	71,25	65,25	67,00	76,00	76,00
Median	50,50	47,50	45,00	52,00	55,00
25 <sup>th</sup> percentile	38,00	33,00	35,00	39,00	38,00
5 <sup>th</sup> percentile	26,15	24,10	24,00	22,60	25,20
Min	15,00	14,00	16,00	13,00	20,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	-----	-----

**Comments:**  
The proportion of primary cases with locally confined carcinoma and high risk decreased compared with the previous year, both in relation to all primary cases (25.3% vs. 26.1%) and in relation to the collective of primary cases with locally confined prostate cancer (30.3% vs. 31.5%). Median treatment in the centres was 55 primary cases in this tumour stage (previous year: 52).

1c. Patients with new recurrence and/or distant metastasis



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Number	Patients with new recurrence and/or distant metastases	33	1 - 142	6201
	No target value			




	2019	2020	2021	2022	2023
Max	-----	157,00	137,00	215,00	142,00
95 <sup>th</sup> percentile	-----	101,65	92,90	90,05	100,25
75 <sup>th</sup> percentile	-----	48,75	50,00	50,25	48,50
Median	-----	27,50	27,00	30,00	33,00
25 <sup>th</sup> percentile	-----	15,00	13,50	14,75	15,00
5 <sup>th</sup> percentile	-----	6,00	4,10	3,00	5,15
Min	-----	1,00	1,00	1,00	1,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
164	99.39%	-----	-----

**Comments:**  
The number of patients with newly occurring recurrence and/or distant metastases increased by 15%, which is significantly higher than the increase in the number of certified centres (+7.9%). A median of 33 patients with a new event (recurrence and/or distant metastasis) were treated (previous year: 30).

## 2a. Presentation in the weekly pre-therapeutic tumour board – via Urology



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator presented in the pre-therapeutic tumour board	150*	44 - 2453	34331
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to Radical Cystoprostatectomy (CPE)).	152*	44 - 2500	35001
Rate	Target value ≥ 95%	99.22%	62.07% - 100%	98.09% **



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	98.50%	98.34%	99.07%	98.88%	99.22%
25 <sup>th</sup> percentile	96.07%	95.90%	97.08%	97.30%	97.44%
5 <sup>th</sup> percentile	88.53%	81.01%	92.65%	94.65%	94.04%
Min	49.11%	62.03%	79.61%	28.09%	62.07%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	153	92.73%


### Comments:

The centres have been successfully implementing the indicator at a very high level for years. However, despite a further increase in the median/total rate, the proportion of centres meeting the target value has declined compared with the previous year (92.7% vs. 94.8%). The centres with presentation rates of less than 95% cited reasons such as staff shortages (due to sickness) and external boards and direct allocation to surgery, but also admitted to mistakes.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

## 2b. Presentation in the weekly pre-therapeutic tumour board – via Radiotherapy



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator presented in the pre-therapeutic tumour board	25*	1 - 187	4973
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to CPE).	25*	1 - 188	5090
Rate	Target value ≥ 95%	100%	40.00% - 100%	97.70%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	100%	99.29%	100%	100%	99.38%
5 <sup>th</sup> percentile	88.81%	80.06%	89.20%	90.28%	89.90%
Min	50.00%	30.43%	68.89%	33.33%	40.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
148	89.70%	138	93.24%


### Comments:

The centres have been presenting their cases at the pre-therapy conference (radiotherapy) at a very high level for years. Ten centres (previous year: eight) fell short of the target value, citing a lack of awareness and limited human resources, particularly in connection with staff turnover. The centres stated that patients had already been discussed externally in an interdisciplinary board or that urological consultations had taken place, and responded with service instructions and quality circles. The auditors made critical remarks in nine centres.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

### 3a. Presentation in the weekly tumour board – Primary cases post-operative



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients total
Numerator	Patients of the denominator presented at the tumour board (post-operative: primary cases operated)	44*	7 - 1143	11007
Denominator	Primary cases > pT3a and/or R1 and/or pN+	46*	7 - 1168	11979
Rate	Target value = 100%	100%	39.07% - 100%	91.89%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	100%	100%	100%	100%	96.61%
5 <sup>th</sup> percentile	90.35%	88.13%	95.49%	95.65%	66.08%
Min	41.33%	57.14%	75.00%	21.74%	39.07%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	112	67.88%


#### Comments:

Following modification of the denominator and the newly introduced requirement to report primary cases with T category pT3a (previously > pT3a), the centres are still experiencing difficulties with implementation. Nevertheless, a median of 100% of primary cases ≥ pT3a u.o. R1 u.o. pN+ were presented postoperatively at the tumour board in the centres.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

### 3b. Presentation in the weekly tumour board – Primary cases primary M1 pre-therapeutic



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator presented at the tumour board (pre-therapeutic: primary M1).	17*	1 - 55	3055
Denominator	Primary cases with primary M1	17*	1 - 56	3076
Rate	Target value = 100%	100%	81.82% - 100%	99.32%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	100%	100%	100%	100%	100%
5 <sup>th</sup> percentile	87.61%	77.52%	94.12%	91.56%	97.06%
Min	72.73%	53.13%	80.00%	76.92%	81.82%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	153	92.73%


#### Comments:

Even after changing the tumour board meeting frequency from monthly to weekly, the centres continue to achieve the usual high standard in the pre-treatment presentation of primary cases with primary distant metastases. 99.3% of primary cases with distant metastases are presented to the tumour board prior to treatment (previous year: 99.1%). The proportion of centres meeting the target value increased from 90.8% to 92.7%.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

### 3c. Presentation in the weekly tumour board: Patients with new recurrence and/or distant metastases pre-therapeutic



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator presented at the tumour board (pre-therapeutic: recurrence/distant metastasis).	31.5*	0 - 139	6042
Denominator	Patients with new recurrence and/or distant metastases (= indicator 1c)	33*	1 - 142	6201
Rate	Target value = 100%	100%	0.00% - 100%	97.44%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	96.58%	92.86%	96.29%	99.00%	100%
5 <sup>th</sup> percentile	71.82%	60.00%	73.14%	77.83%	83.69%
Min	0.00%	20.00%	50.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
164	99.39%	125	76.22%

#### Comments:


Since the indicator year 2023, a weekly tumour board has also been required for the presentation of patients with new events (recurrence and/or metastases). Both the overall rate and the proportion of centres meeting the target value have increased. Thirty-nine centres did not present all patients to the tumour board, citing omissions, external follow-up treatment and patient deaths as reasons. In the centre with a 0% rate, a single case of brain metastasis was discussed in the neuro board.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.




## 4. Active Surveillance (AS) (GL QI)



Begründungspflicht = mandatory justification

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases under AS	12*	0 - 98	2685
Denominator	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and Gleason-Score 6 and cT category ≤ 2a)	36*	4 - 377	7484
Rate	Mandatory justification*** <0.01%	36.84%	0.00% - 100%	35.88%* *



	2019	2020	2021	2022	2023
Max	88.89%	91.30%	95.24%	100%	100%
95 <sup>th</sup> percentile	69.52%	70.97%	77.71%	77.95%	83.95%
75 <sup>th</sup> percentile	47.91%	50.00%	50.00%	52.38%	54.38%
Median	31.42%	31.71%	34.38%	35.48%	36.84%
25 <sup>th</sup> percentile	11.35%	15.66%	15.38%	14.29%	14.71%
5 <sup>th</sup> percentile	0.95%	3.22%	0.00%	1.38%	0.07%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
165	100.00%	156	94.55%

### Comments:


The proportion of patients undergoing active surveillance in primary cases with localised risk and low risk continued to grow across almost the entire spectrum in the indicator year 2023 and now stands at 35.9% overall (previous year: 32.8%). In nine centres, no patients were referred to AS, which was justified by targeted referral to interventional therapy and the express wish of the patient. Three centres identified documentation deficits in the recording of active surveillance patients.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


\*\* Percentage of total patients treated in centers according to the numerator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.

## 5. Percutaneous radiotherapy with hormone ablation therapy for locally confined PCa with high risk (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with additional neo- and/or adjuvant hormone ablative therapy	10*	0 - 38	1967
Denominator	Primary cases with prostate cancer T1-2 N0 M0 with high risk (PSA >20ng/ml or Gleason-Score ≥ 8 or cT category 2c) and percutaneous radiotherapy	13*	1 - 54	2487
Rate	Target value ≥ 70%	80.00%	0.00% - 100%	79.09%* *



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	94.27%	93.94%	94.44%	92.15%	93.18%
Median	80.00%	84.62%	82.69%	81.82%	80.00%
25 <sup>th</sup> percentile	62.62%	65.16%	72.22%	71.43%	72.22%
5 <sup>th</sup> percentile	24.69%	23.64%	39.72%	50.00%	46.73%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
164	99.39%	133	81.10%


### Comments:

The proportion of patients receiving neoadjuvant or adjuvant hormone ablation therapy in primary cases with locally limited risk (high risk) and percutaneous radiation has continued to decline slightly. Thirty-one centres (previous year: 32) did not meet the target value, citing patient refusal of Androgen deprivation therapy (ADT), a decision against ADT after consideration of cardiovascular risk, and external follow-up treatment as reasons.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

## 6. Psycho-oncological distress screening



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator who were psycho-oncologically screened	127*	1 - 2436	20806
Denominator	Primary cases (= indicator 1a) and patients with new recurrence and/or distant metastases (= Indicator 1c)	254,5*	101 - 2787	35815
Rate	Target value ≥ 65%	55.47%	0.58% - 99.77%	58.09%**



		2019	2020	2021	2022	2023
●	Max	----	----	----	----	99.77%
	95 <sup>th</sup> percentile	----	----	----	----	88.45%
	75 <sup>th</sup> percentile	----	----	----	----	69.09%
	Median	----	----	----	----	55.47%
	25 <sup>th</sup> percentile	----	----	----	----	36.11%
	5 <sup>th</sup> percentile	----	----	----	----	14.69%
●	Min	----	----	----	----	0.58%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
116	70.30%	42	36.21%


### Comments:

The indicator for recording psycho-oncological distress screening was collected for the first time and is optional. It therefore only provides a snapshot of the situation. With a wide range (1%–100%), a median of 55.5% of patients were screened. The centres with rates < 65% cited reasons such as the start of routine screening during the year, deficits in the screening of specific patient groups (e.g. patients undergoing radiotherapy, outpatients, Active Surveillance (AS)), but also difficulties in documentation.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

## 7. Social service counselling



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator who received counselling from the social service on an inpatient or outpatient basis	120*	1 - 1123	25689
Denominator	Primary cases (= indicator 1a) and patients with new recurrence and/or distant metastases (= indicator 1c)	251*	101 - 2787	51083
Rate	Mandatory justification*** <50%	53.74%	0.28% - 94.41%	50.29%**



	2019	2020	2021	2022	2023
Max	91.22%	91.87%	92.61%	89.30%	94.41%
95 <sup>th</sup> percentile	77.00%	75.69%	75.16%	76.99%	80.20%
75 <sup>th</sup> percentile	60.45%	60.00%	64.02%	64.02%	64.20%
Median	51.56%	50.61%	53.77%	53.27%	53.74%
25 <sup>th</sup> percentile	39.66%	36.68%	39.65%	39.77%	40.33%
5 <sup>th</sup> percentile	4.65%	2.88%	2.45%	4.01%	3.53%
Min	0.00%	0.37%	0.37%	0.84%	0.28%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
165	100.00%	103	62.42%

### Comments:


The indicator for recording counselling by social services has remained stable for years. The centres with rates of less than 50% stated, among other things, that a large number of patients had refused the counselling offer. Other centres identified gaps in care for primary cases with active surveillance or definitive radiotherapy, or for patients with recurrence or secondary distant metastasis.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.

8. Patients enrolled in a study



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients who were included in a study with an ethical vote	72*	1 - 3157	19631
Denominator	Primary cases (= indicator 1a)	211*	100 - 2667	44882
Rate	Target value ≥5%	34.97%	0.74% - 209.38%	43.74%**



	2019	2020	2021	2022	2023
Max	345.43%	242.61%	153.45%	163.53%	209.38%
95 <sup>th</sup> percentile	105.88%	90.12%	80.80%	75.59%	80.84%
75 <sup>th</sup> percentile	52.99%	55.16%	52.35%	45.35%	50.54%
Median	39.09%	39.36%	38.39%	35.14%	34.97%
25 <sup>th</sup> percentile	23.24%	24.31%	25.58%	23.20%	25.29%
5 <sup>th</sup> percentile	7.41%	7.14%	10.47%	5.88%	7.81%
Min	0.00%	0.00%	0.88%	1.51%	0.74%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	162	98.18%

**Comments:**  
With almost 20,000 study inclusions, the study rate is 43.7%, which is 3.4 percentage points higher than in the previous year. With the median remaining virtually unchanged, the rate has otherwise risen across the entire range. Three centres (previous year: six) included less than 5% of their patients in a study in relation to the number of primary cases. After including patients in PCO (Prostate Cancer Outcome study), ProNAT (Prostate Cancer Registry Database) (and prospectively ARISTA) (Impact of topical microporous polysaccharide hemospheres on erectile dysfunction) , among others, the centres reported higher rates in 2024 in evaluations conducted during the year.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.


## Individual Annual Report - Benchmark

### Individual Annual Report - Evaluation of site-specific key figures

#### What is the individual Annual Report?

In the individual annual report, the site-specific centre data is shown and compared to the other certified centres in the respective certification system of the German Cancer Society. In addition, the individual development of the centre is presented over the course of time.

The content and design of an individual Annual Report are based on the general Annual Reports. An example of an individual Annual Report is available at [www.onkoziert.de](http://www.onkoziert.de) under General Information / Annual Reports.



Example centre (red bar) compared to the other certified centres

#### Who can receive the individual Annual Report?

The prerequisite for the preparation of the individual annual report is the publication of the general annual report (announcement on [www.onkoziert.de](http://www.onkoziert.de)) as well as the depiction of the own centre in the general Annual Report (for example, centres with initial certification are not depicted in the audit year). In the case of multi-site centres, each site is shown in its own individual Annual Report. Only the general Annual Report is currently available for oncology centres.

	Indicator definition	Example centre				
		2018	2019	2020	2021	2022
Numerator	Patients referred by the denominator who received inpatient or outpatient counselling from social services	219	263	220	240	237
Denominator	Primary cases (= indicator 1a) + patients with newly occurring recurrence (local, regional LN metastases) and/or distant metastases (= indicator 1b)	321	362	331	355	360
Rate	Mandatory justification*** <20%	8,22%	72,65%	66,47%	67,61%	65,83%

Individual development of the example centre over time

**Extract from an individual Annual Report  
(indicator counselling social service)**

## Individual Annual Report - Benchmark

### How can I receive the individual Annual Report?

The individual Annual Report is made available for download as an electronic PowerPoint file on the [Data-WhiteBox](#) platform.

Access to an individual Annual Report differs depending on the certification system:


#### Colorectal, Prostate and Gynaecological Cancer Centres

- The individual Annual Report is made available for all Colorectal, Prostate and Gynaecological Cancer Centres by decision of the respective Certification Commission.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.


#### All other Organ Cancer Centres / Modules

- The centres (centre management and centre coordination) are informed by email by OnkoZert about the basic availability of the individual Annual Reports. From this point onwards, an individual Annual Report can optionally be ordered for a fee.
- The 'Individual Annual Report Order Form' is available at [www.onkozert.de](http://www.onkozert.de) under General Information / Annual Reports. Orders can only be placed by persons who are registered with OnkoZert as contact persons (e.g. centre management, centre coordination, QMB, etc.)
- The costs for the respective individual Annual Reports are listed on the form.
- The preparation time is approx. 3 weeks after receipt of order.

9. Surgical expertise



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Number	Radical prostatectomies (RPE) / total cystoprostatectomies (RCE) (see Basic Data)	108	33 - 2507	28058
	Target value ≥ 50			




	2019	2020	2021	2022	2023
Max	2642,00	2549,00	2565,00	2358,00	2507,00
95 <sup>th</sup> percentile	372,90	390,90	420,00	451,40	440,80
75 <sup>th</sup> percentile	166,50	146,75	163,00	180,00	182,00
Median	84,00	84,50	97,00	96,00	108,00
25 <sup>th</sup> percentile	60,75	59,00	61,00	68,00	75,00
5 <sup>th</sup> percentile	40,75	38,55	42,20	47,00	50,20
Min	27,00	19,00	34,00	33,00	33,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	159	96.36%


**Comments:**  
The number of prostatectomies has increased across almost the entire range; the 25th percentile and median in particular show a significant increase. Six centres (previous year: 10) performed fewer than 50 RPE/RCE and reported rising numbers for 2024 following the introduction of robotic surgery. Other reasons included robotically performed procedures at non-certified clinical sites and surgery capacity restrictions due to sickness.



## 10. Record of R1 resections for (y)pT2 c / pN0 or Nx M0



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Surgeries of the denominator with R1	7*	0 - 115	1596
Denominator	Operations on primary cases with (y)pT2 c/pN0 or Nx M0	66*	18 - 1404	16406
Rate	Target value ≤ 15%	10.32%	0.00% - 27.27%	9.73%**



	2019	2020	2021	2022	2023
Max	29.27%	38.71%	31.43%	35.29%	27.27%
95 <sup>th</sup> percentile	19.97%	22.07%	19.77%	20.99%	20.84%
75 <sup>th</sup> percentile	13.57%	13.82%	14.29%	13.10%	14.29%
Median	9.54%	9.81%	9.09%	8.73%	10.32%
25 <sup>th</sup> percentile	5.37%	5.72%	4.21%	5.48%	5.88%
5 <sup>th</sup> percentile	0.00%	0.00%	0.11%	0.00%	1.25%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	138	83.64%

### Comments:


The R1 resection rate has risen slightly and is above 10% for the first time. 20 of the 24 centres with conspicuous indicators in the previous year have reduced their R1 resection rate; however, 4 of these centres remain above 15%. In the current indicator year, 27 centres exceeded the target value of ≤ 15%. In 6 audits, deviations occurred due to multifocal R1 situations or positive margins > 3 mm. 3 centres received a certificate extension with limited validity (12 months) due to high R1 rates.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


\*\* Percentage of total patients treated in centers according to the numerator.

## 11. Definitive radiotherapy

Rate



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with definitive radiotherapy	42*	0 - 199	7864
Denominator	Primary cases (= indicator 1a)	211*	100 - 2667	44882
Rate	Mandatory justification*** <10% and >90%	19.51%	0.00% - 60.00%	17.52%**



	2019	2020	2021	2022	2023
Max	52.45%	61.26%	58.79%	56.83%	60.00%
95 <sup>th</sup> percentile	42.23%	41.40%	44.24%	43.81%	45.62%
75 <sup>th</sup> percentile	30.09%	29.02%	27.08%	28.69%	26.37%
Median	18.75%	18.56%	18.80%	17.27%	19.51%
25 <sup>th</sup> percentile	11.16%	12.18%	10.64%	10.87%	11.00%
5 <sup>th</sup> percentile	2.81%	3.48%	3.33%	3.95%	4.11%
Min	0.13%	1.00%	0.06%	0.06%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
165	100.00%	131	79.39%

### Comments:

The number of primary cases with definitive radiotherapy (+16.9%) rose disproportionately again this year compared with the total number of primary cases (+12.4%). 17.5% of all primary cases (previous year: 16.8%) received radiotherapy. In 34 centres, the proportion of primary cases treated with radiotherapy was < 10%. These centres reported that patients decided against radiotherapy after receiving open-ended information, and that they were supraregional centres (robotic centres).


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.


## 12. Permanent seed implantation - D 90 > 130 Gy

Rate



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator in which D90 > 130 Gy was achieved	11*	1 - 68	354
Denominator	Primary cases with LDR mono-therapy	11*	1 - 68	359
Rate	Target value ≥ 90%	100%	93.33% - 100%	98.61%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	100%	99.31%	100%	100%	100%
5 <sup>th</sup> percentile	93.75%	67.86%	66.67%	92.68%	93.33%
Min	79.49%	0.00%	66.67%	91.67%	93.33%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
21	12.73%	21	100.00%


### Comments:

The number of primary cases treated with LDR monotherapy rose significantly again (+111 = +45%) after strong growth last year (+33%). A total of 359 patients were treated with permanent seed implantation; in 4 primary cases, a D 90 > 130 Gy was achieved (= 1.4%). All 21 centres in which at least 1 primary case (median 11) was treated with LDR monotherapy met the target value of ≥ 90%.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

### 13. HDR brachytherapy



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with HDR brachytherapy	0*	0 - 32	137
Denominator	Primary cases (= indicator 1a)	211*	100 - 2667	44882
Rate	No target value	0.00%	0.00% - 16.49%	0.31%**



	2019	2020	2021	2022	2023
Max	15.97%	21.43%	15.63%	17.98%	16.49%
95 <sup>th</sup> percentile	5.30%	3.79%	1.90%	2.96%	1.91%
75 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Median	0.00%	0.00%	0.00%	0.00%	0.00%
25 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
5 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	----	----


#### Comments:

HDR brachytherapy was performed in 19 centres (previous year: 20) in primary cases. The absolute number of primary cases treated with HDR brachytherapy remained at the same level as in the two previous years (138 and 141 primary cases, respectively). In 10 centres, the proportion of HDR brachytherapy increased (median +0.7 percentage points), while in 13 centres the proportion was slightly lower (-0.8 percentage points).

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


\*\* Percentage of total patients treated in centers according to the numerator.

## 14. Diagnostic report – Punch biopsy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with complete diagnostic report	175*	46 - 2148	37220
Denominator	Primary cases with punch biopsy	175*	46 - 2665	39135
Rate	Target value $\geq 90\%$	98.47%	67.71% - 100%	95.11%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	99.56%	99.71%	99.57%	100%	100%
Median	94.62%	96.82%	97.05%	97.97%	98.47%
25 <sup>th</sup> percentile	84.92%	86.00%	88.89%	90.64%	93.84%
5 <sup>th</sup> percentile	55.83%	53.00%	80.62%	81.28%	89.36%
Min	18.73%	0.90%	27.83%	46.00%	67.71%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	156	94.55%


### Comments:

The GL QI shows better implementation across the entire spectrum. With a slight increase in the median, the overall rate rose from 86.8% to 95.1%. Even after raising the target value in the current indicator year from  $\geq 80\%$  to  $\geq 90\%$ , 94.6% of centres are above the cut-off. In 9 centres, > 10% of all findings were incomplete: these centres cited imperfections in external findings (and completeness of findings by their own pathology department).


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator..

## 15. Diagnostic report – Lymph nodes (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with diagnostic reports stating: • pN category • number of affected lymph nodes in relation to resected lymph nodes	94*	12 - 1814	23543
Denominator	Primary cases with lymphadenectomy	97*	12 - 1820	23799
Rate	Target value ≥ 80%	100%	83.52% - 100%	98.92%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	98.50%	98.79%	98.91%	98.00%	98.65%
5 <sup>th</sup> percentile	91.79%	93.12%	94.65%	91.11%	93.08%
Min	68.18%	60.87%	82.71%	80.36%	83.52%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	165	100.00%


### Comments:

Since the mandatory statement of reasons requirement was changed from < 10% to a target value of ≥ 80% in the 2021 indicator year, all centres have met the certification requirement without exception. Overall, 99% of the findings from all centres contained all the required information.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

## 16. Begin salvage-radiotherapy (SRT) for recurrent Prostate Cancer (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator with beginning SRT and PSA <0.5 ng/ml	6*	0 - 50	1456
Denominator	Patients after PE and PSA recurrence and SRT	7*	1 - 71	1855
Rate	Target value ≥ 70%	84.50%	0.00% - 100%	78.49%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	98.08%	100%	100%	100%	100%
Median	80.00%	81.82%	82.71%	81.48%	84.50%
25 <sup>th</sup> percentile	67.28%	72.73%	70.98%	72.11%	72.60%
5 <sup>th</sup> percentile	39.63%	37.45%	39.00%	50.00%	33.33%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
160	96.97%	127	79.38%


### Comments:

With a slight decline in the overall rate, implementation of the GL QI remained virtually unchanged. The centres with rates < 70% cited delayed referral (PSA ≥ 0.5) by external treatment providers and a postponement of the start of treatment requested by patients.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


\*\* Percentage of total patients treated in centers according to the numerator.

## 17. Postoperative complications after radical prostatectomy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with complications Clavien-Dindo grade III or IV within the first 6 months after radical prostatectomy (RPE)	2*	0 - 71	569
Denominator	Primary T1-2 N0 M0 and RPE (from the previous indicator year)	57*	17 - 1438	15521
Rate	Target value ≤ 15%	3.45%	0.00% - 33.33%	3.67%**



	2019	2020	2021	2022	2023
Max	-----	-----	20.00%	29.41%	33.33%
95 <sup>th</sup> percentile	-----	-----	13.61%	10.60%	12.20%
75 <sup>th</sup> percentile	-----	-----	8.33%	6.06%	6.32%
Median	-----	-----	3.95%	3.48%	3.45%
25 <sup>th</sup> percentile	-----	-----	0.47%	0.68%	0.00%
5 <sup>th</sup> percentile	-----	-----	0.00%	0.00%	0.00%
Min	-----	-----	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
161	97.58%	159	98.76%

### Comments:


With the median remaining virtually unchanged, the overall complication rate fell slightly from 4.1% to 3.7% compared with the previous year. Two centres (previous year: 3) exceeded the target value of ≤ 15% and reported the following complications: lymphoceles (9 patients), post-operative bleeding/haematomas (3 patients), urinary retention, anastomotic leakage and rectal injury (1 patient each).

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


\*\* Percentage of total patients treated in centers according to the numerator.



## 18. Adverse effects after radiotherapy (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with complications CTCAE grade III or IV within the first 6 months after radiotherapy	0*	0 - 6	40
Denominator	Primary cases with definitive radiotherapy (from the previous indicator year)	46,5*	1 - 228	8245
Rate	Target value ≤ 3.5%	0.00%	0.00% - 16.67%	0.49%**



	2019	2020	2021	2022	2023
Max	16.67%	9.09%	4.88%	6.90%	16.67%
95 <sup>th</sup> percentile	3.55%	2.73%	1.81%	2.26%	2.70%
75 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Median	0.00%	0.00%	0.00%	0.00%	0.00%
25 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
5 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
160	96.97%	158	98.75%


### Comments:

In the indicator year 2023, higher-grade adverse effects (CTCAE grade III/IV) were documented in 40 primary cases in the first 6 months after radiotherapy. At 0.5%, the proportion of adverse effects is roughly the same as in the previous year (0.3%). In the two centres that had been unremarkable for years, with current rates > 3.5%, 1 and 2 primary cases had radiation cystitis and urinary retention, respectively.


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

## 19. Dental examination prior to commencement of bisphosphonate or denosumab therapy (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Patients of the denominator with recommendation of a dental examination before the start of bisphosphonate or denosumab therapy.	3*	0 - 45	706
Denominator	Patients with bisphosphonate or denosumab therapy	3*	1 - 46	737
Rate	Target value $\geq 90\%$	100%	0.00% - 100%	95.79%**



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	50.00%	60.00%	100%	100%	100%
5 <sup>th</sup> percentile	0.00%	0.00%	50.00%	83.23%	50.00%
Min	0.00%	0.00%	0.00%	33.33%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
135	81.82%	122	90.37%


### Comments:

In 30 of 165 centres, no patients received osteoprotective therapy; 122 centres met the target value. In 13 centres (previous year: 7/115), a dental examination was recommended for  $< 90\%$  of patients with bisphosphonates/denosumab before initiation of therapy. These centres justified falling short of the target with documentation deficits (pre-existing therapy, external initiation, lack of written documentation), urgent initiation of therapy (tumour pain, poor general condition) and language barriers


\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

20. No hormone ablation therapy in the case of locally advanced Prostate Cancer with radical prostatectomy (GL QI) Certification



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with adjuvant hormone ablation therapy	0*	0 - 16	44
Denominator	Primary cases pT3-4 pN0 M0 and RPE	27*	2 - 768	7282
Rate	Target value < 0.1%	0.00%	0.00% - 30.77%	0.60%**




	2019	2020	2021	2022	2023
Max	50.00%	30.00%	25.00%	28.57%	30.77%
95 <sup>th</sup> percentile	13.83%	11.40%	9.43%	9.30%	3.94%
75 <sup>th</sup> percentile	1.77%	0.00%	0.00%	0.00%	0.00%
Median	0.00%	0.00%	0.00%	0.00%	0.00%
25 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
5 <sup>th</sup> percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	147	89.09%


**Comments:**  
With the GL QI already very well implemented, the positive trend continues: both the proportion and absolute number of patients receiving hormone ablation therapy continue to decline compared with previous years. In 18 centres (2022: 26), primary cases with locally advanced carcinoma according to RPE received hormone ablation therapy, justified by persistent PSA elevation, R1 resection and bridging therapy for secondary carcinoma, among other reasons. In addition, centres reported initiation of therapy in follow-up treatment in private practice.

\*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.  
\*\* Percentage of total patients treated in centers according to the numerator.

## 21. Focal therapy for locally advanced Prostate Cancer (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator who received focal therapy	0*	0 - 0	0
Denominator	Primary cases with locally advanced prostate cancer	8*	1 - 157	1917
Rate	Target value < 0.1%	0%	0% - 0%	0.00%**




	2019	2020	2021	2022	2023
Max	----	----	11.11%	0.00%	0.00%
95 <sup>th</sup> percentile	----	----	0.00%	0.00%	0.00%
75 <sup>th</sup> percentile	----	----	0.00%	0.00%	0.00%
Median	----	----	0.00%	0.00%	0.00%
25 <sup>th</sup> percentile	----	----	0.00%	0.00%	0.00%
5 <sup>th</sup> percentile	----	----	0.00%	0.00%	0.00%
Min	----	----	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
153	92.73%	153	100.00%


### Comments:

As in the previous indicator year, not a single primary case with locally advanced cancer was treated focally. Overall, since the indicator was introduced, only 2 out of 5,725 primary cases with locally advanced cancer (= 0.035%) received focal therapy.

22. Rate of locally confined Prostate Cancer and low risk with RPE/RCE (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with locally confined prostate carcinoma and low risk	13*	0 - 361	3450
Denominator	Primary cases with RPE + RCE	102*	33 - 2492	26921
Rate	No target value	11,32%	0.00% - 56.00%	12.82%**




	2019	2020	2021	2022	2023
Max	----	----	----	----	56.00%
95 <sup>th</sup> percentile	----	----	----	----	27.17%
75 <sup>th</sup> percentile	----	----	----	----	16.84%
Median	----	----	----	----	11.32%
25 <sup>th</sup> percentile	----	----	----	----	7.87%
5 <sup>th</sup> percentile	----	----	----	----	3.01%
Min	----	----	----	----	0.00%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	----	----

**Comments:**  
The proportion of patients with locally confined prostate cancer and low risk classification in the total number of primary cases with radical prostatectomy/cystectomy was calculated for the first time in the indicator year 2023. 12.8% of all primary cases with RPE/RCE (median 11.3%) had such low-risk prostate cancer (range 0-56%).

23. RPE/RCE in primary cases with locally confined Prostate Cancer and low risk (GL QI)



	Definition of indicator	All clinical sites 2023		
		Median	Range	Patients Total
Numerator	Primary cases with locally confined prostate carcinoma and low risk and RPE/RCE	13*	0 - 361	3450
Denominator	Primary cases with locally confined prostate carcinoma and low risk	36*	4 - 377	7484
Rate	No target value	38.46%	0.00% - 99.63%	46.10%**



	2019	2020	2021	2022	2023
Max	----	----	----	----	99.63%
95 <sup>th</sup> percentile	----	----	----	----	83.91%
75 <sup>th</sup> percentile	----	----	----	----	57.89%
Median	----	----	----	----	38.46%
25 <sup>th</sup> percentile	----	----	----	----	23.71%
5 <sup>th</sup> percentile	----	----	----	----	7.71%
Min	----	----	----	----	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
165	100.00%	----	----

**Comments:**  
The proportion of primary cases requiring surgery (RPE/RCE) among primary cases with locally limited, low-risk carcinoma is also reported for the first time: 46% of this patient group underwent surgical treatment. Here, too, there is a wide range of treatments, from 0 to 100% (median 38.5%).

# WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on [www.krebsgesellschaft.de](http://www.krebsgesellschaft.de)

## Authors

German Cancer Society (DKG)  
Certification Committee Prostate Cancer Centres  
Martin Burchardt, Chair Certification Committee  
Jan Fichtner, Chair Certification Committee  
Manije Sabet, German Cancer Society (DKG)  
Martin Utzig, German Cancer Society (DKG)  
Ellen Griesshammer, German Cancer Society (DKG)  
Nele Grapentin, German Cancer Society (DKG)  
Daniela Miller, OnkoZert  
Roxana Rentea, OnkoZert

## Imprint

Publisher and responsible for content:  
Deutsche Krebsgesellschaft (DKG)  
Kuno-Fischer-Straße 8  
14057 Berlin  
Tel: +49 (030) 322 93 29 0  
Vereinsregister Amtsgericht Charlottenburg.  
Vereinsregister-Nr.: VR 27661 B  
V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with:  
OnkoZert. Neu-Ulm  
[www.onkozert.de](http://www.onkozert.de)

Version e-A1-en; 29.04.2025

ISBN: 978-3-910336-94-0

